βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion

American Journal of Pathology

Volumn 184, Issue 3, 2014, Pages 609-617

  Tsourlakis, Maria C ^a   Weigand, Philipp ^a   Grupp, Katharina ^a   Kluth, Martina ^a   Steurer, Stefan ^a   Schlomm, Thorsten ^a   Graefen, Markus ^a   Huland, Hartwig ^a   Salomon, Georg ^a   Steuber, Thomas ^a   Wilczak, Waldemar ^a   Sirma, Hüseyin ^a   Simon, Ronald ^a   Sauter, Guido ^a   Minner, Sarah ^a   Quaas, Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ERG PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; PTEN PROTEIN, HUMAN; SERINE PROTEINASE; TMPRSS2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUBULIN; TUMOR MARKER;

AGED; CANCER GRADING; DISEASE COURSE; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; TISSUE MICROARRAY; TUMOR RECURRENCE;

AGED; BIOMARKERS, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SEQUENCE DELETION; SERINE ENDOPEPTIDASES; TISSUE ARRAY ANALYSIS; TRANS-ACTIVATORS; TUBULIN;

EID: 84894182337     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.11.007     Document Type: Article

References (43)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
3. G.A. Orr, P. Verdier-Pinard, H. McDaid, and S.B. Horwitz Mechanisms of Taxol resistance related to microtubules Oncogene 22 2003 7280 7295 (Pubitemid 37487160)
4. C.D. Katsetos, M.M. Herman, and S.J. Mork Class III beta-tubulin in human development and cancer Cell Motil Cytoskeleton 55 2003 77 96 (Pubitemid 36627260)
5. C.D. Katsetos, E. Draberova, A. Legido, C. Dumontet, and P. Draber Tubulin targets in the pathobiology and therapy of glioblastoma multiforme, I: class III beta-tubulin J Cell Physiol 221 2009 505 513
6. Y. Koh, B. Jang, S.W. Han, T.M. Kim, D.Y. Oh, S.H. Lee, C.H. Kang, D.W. Kim, S.A. Im, D.H. Chung, Y.T. Kim, T.Y. Kim, Y.W. Kim, J.H. Kim, D.S. Heo, and Y.J. Bang Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer J Thorac Oncol 5 2010 320 325
7. G. Ferrandina, G.F. Zannoni, E. Martinelli, A. Paglia, V. Gallotta, S. Mozzetti, G. Scambia, and C. Ferlini Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients Clin Cancer Res 12 2006 2774 2779
8. T.E. Hetland, E. Hellesylt, V.A. Florenes, C. Trope, B. Davidson, and J. Kaern Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance Hum Pathol 42 2011 1019 1026
9. J.W. Choi, Y. Kim, J.H. Lee, and Y.S. Kim Expression of β-tubulin isotypes in urothelial carcinoma of the bladder World J Urol 2012 10.1007/s00345-012-0993-z [Epub ahead of print]
10. Y. Koh, T.M. Kim, Y.K. Jeon, T.K. Kwon, J.H. Hah, S.H. Lee, D.W. Kim, H.G. Wu, C.S. Rhee, M.W. Sung, C.W. Kim, K.H. Kim, and D.S. Heo Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma Ann Oncol 20 2009 1414 1419
11. H.L. Zhang, L. Ruan, L.M. Zheng, D. Whyte, C.M. Tzeng, and X.W. Zhou Association between class III beta-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis Lung Cancer 77 2012 9 15
12. X. Chen, J. Wu, H. Lu, O. Huang, and K. Shen Measuring beta-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer Cancer Sci 103 2012 262 268
13. W.E. Zheng, H. Chen, S.F. Yuan, L.L. Wu, W. Zhang, H.Y. Sun, and W.J. Chen Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer J BUON 17 2012 284 290
14. G. Ploussard, S. Terry, P. Maille, Y. Allory, N. Sirab, L. Kheuang, P. Soyeux, N. Nicolaiew, E. Coppolani, B. Paule, L. Salomon, S. Culine, R. Buttyan, F. Vacherot, and A. de la Taille Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy Cancer Res 70 2010 9253 9264
15. L. Egevad, A. Valdman, N.P. Wiklund, P. Seve, and C. Dumontet Beta-tubulin III expression in prostate cancer Scand J Urol Nephrol 44 2010 371 377
16. K. Grupp, F. Diebel, H. Sirma, R. Simon, K. Breitmeyer, S. Steurer, C. Hube-Magg, K. Prien, T. Pham, P. Weigand, U. Michl, H. Heinzer, M. Kluth, S. Minner, M.C. Tsourlakis, J.R. Izbicki, G. Sauter, T. Schlomm, and W. Wilczak SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence Prostate 73 2013 1690 1698
17. T. Schlomm, L. Iwers, P. Kirstein, B. Jessen, J. Kollermann, S. Minner, A. Passow-Drolet, M. Mirlacher, K. Milde-Langosch, M. Graefen, A. Haese, T. Steuber, R. Simon, H. Huland, G. Sauter, and A. Erbersdobler Clinical significance of p53 alterations in surgically treated prostate cancers Mod Pathol 21 2008 1371 1378
18. J. Kononen, L. Bubendorf, A. Kallioniemi, M. Barlund, P. Schraml, S. Leighton, J. Torhorst, M.J. Mihatsch, G. Sauter, and O.P. Kallioniemi Tissue microarrays for high-throughput molecular profiling of tumor specimens Nat Med 4 1998 844 847 (Pubitemid 28331029)
19. S. Minner, M. Enodien, H. Sirma, A.M. Luebke, A. Krohn, P.S. Mayer, R. Simon, P. Tennstedt, J. Muller, L. Scholz, J.C. Brase, A.Y. Liu, H. Schluter, K. Pantel, U. Schumacher, C. Bokemeyer, T. Steuber, M. Graefen, G. Sauter, and T. Schlomm ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin Cancer Res 17 2011 5878 5888
20. L. Burkhardt, S. Fuchs, A. Krohn, S. Masser, M. Mader, M. Kluth, F. Bachmann, H. Huland, T. Steuber, M. Graefen, T. Schlomm, S. Minner, G. Sauter, H. Sirma, and R. Simon CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer Cancer Res 73 2013 2795 2805
21. M. Kluth, J. Hesse, A. Heinl, A. Krohn, S. Steurer, H. Sirma, R. Simon, P.S. Mayer, U. Schumacher, K. Grupp, J.R. Izbicki, K. Pantel, E. Dikomey, J.O. Korbel, C. Plass, G. Sauter, T. Schlomm, and S. Minner Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions Mod Pathol 26 2013 975 983
22. A. Krohn, T. Diedler, L. Burkhardt, P.S. Mayer, C. De Silva, M. Meyer-Kornblum, D. Kotschau, P. Tennstedt, J. Huang, C. Gerhauser, M. Mader, S. Kurtz, H. Sirma, F. Saad, T. Steuber, M. Graefen, C. Plass, G. Sauter, R. Simon, S. Minner, and T. Schlomm Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer Am J Pathol 181 2012 401 412
23. A. Krohn, A. Seidel, L. Burkhardt, F. Bachmann, M. Mader, K. Grupp, T. Eichenauer, A. Becker, M. Adam, M. Graefen, H. Huland, S. Kurtz, S. Steurer, M.C. Tsourlakis, S. Minner, U. Michl, T. Schlomm, G. Sauter, R. Simon, and H. Sirma Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers J Pathol 231 2013 130 141
24. S. Minner, C. Wittmer, M. Graefen, G. Salomon, T. Steuber, A. Haese, H. Huland, C. Bokemeyer, E. Yekebas, J. Dierlamm, S. Balabanov, E. Kilic, W. Wilczak, R. Simon, G. Sauter, and T. Schlomm High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer Prostate 71 2011 281 288
25. M.C. Tsourlakis, E. Walter, A. Quaas, M. Graefen, H. Huland, R. Simon, G. Sauter, S. Steurer, T. Schlomm, and S. Minner High Nr-CAM expression is associated with favorable phenotype and late PSA recurrence in prostate cancer treated by prostatectomy Prostate Cancer Prostatic Dis 16 2013 159 164
26. M.F. Berger, M.S. Lawrence, F. Demichelis, Y. Drier, K. Cibulskis, and A.Y. Sivachenko et al. The genomic complexity of primary human prostate cancer Nature 470 2011 214 220
27. J. Lapointe, C. Li, C.P. Giacomini, K. Salari, S. Huang, P. Wang, M. Ferrari, T. Hernandez-Boussard, J.D. Brooks, and J.R. Pollack Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis Cancer Res 67 2007 8504 8510 (Pubitemid 47437424)
28. B.S. Taylor, N. Schultz, H. Hieronymus, A. Gopalan, Y. Xiao, B.S. Carver, V.K. Arora, P. Kaushik, E. Cerami, B. Reva, Y. Antipin, N. Mitsiades, T. Landers, I. Dolgalev, J.E. Major, M. Wilson, N.D. Socci, A.E. Lash, A. Heguy, J.A. Eastham, H.I. Scher, V.E. Reuter, P.T. Scardino, C. Sander, C.L. Sawyers, and W.L. Gerald Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
29. J.I. Epstein, Z. Feng, B.J. Trock, and P.M. Pierorazio Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades Eur Urol 61 2012 1019 1024
30. P. Tennstedt, P. Koster, A. Bruchmann, M. Mirlacher, A. Haese, T. Steuber, G. Sauter, H. Huland, M. Graefen, T. Schlomm, S. Minner, and R. Simon The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers Int J Oncol 40 2012 261 268
31. S. Minner, B. Jessen, L. Stiedenroth, E. Burandt, J. Kollermann, M. Mirlacher, A. Erbersdobler, C. Eichelberg, M. Fisch, T.H. Brummendorf, C. Bokemeyer, R. Simon, T. Steuber, M. Graefen, H. Huland, G. Sauter, and T. Schlomm Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer Clin Cancer Res 16 2010 1553 1560
32. J. Müller, A. Ehlers, L. Burkhardt, H. Sirma, T. Steuber, M. Graefen, G. Sauter, S. Minner, R. Simon, T. Schlomm, and U. Michl Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers Int J Cancer 132 2013 1333 1340
33. S. Minner, F. Kraetzig, M. Tachezy, E. Kilic, M. Graefen, W. Wilczak, C. Bokemeyer, H. Huland, G. Sauter, and T. Schlomm Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer Hum Pathol 42 2011 1946 1952
34. S. Ranganathan, C.A. Benetatos, P.J. Colarusso, D.W. Dexter, and G.R. Hudes Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells Br J Cancer 77 1998 562 566 (Pubitemid 28059462)
35. S. Ranganathan, D.W. Dexter, C.A. Benetatos, and G.R. Hudes Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents Biochim Biophys Acta 1395 1998 237 245 (Pubitemid 28105732)
36. A. Ganguly, H. Yang, and F. Cabral Class III beta-tubulin counteracts the ability of paclitaxel to inhibit cell migration Oncotarget 2 2011 368 377
37. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J.E. Montie, R.B. Shah, K.J. Pienta, M.A. Rubin, and A.M. Chinnaiyan Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648 (Pubitemid 41528150)
38. J. Weischenfeldt, R. Simon, L. Feuerbach, K. Schlangen, D. Weichenhan, and S. Minner et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer Cancer Cell 23 2013 159 170
39. G.M. Birdsey, N.H. Dryden, A.V. Shah, R. Hannah, M.D. Hall, D.O. Haskard, M. Parsons, J.C. Mason, M. Zvelebil, B. Gottgens, A.J. Ridley, and A.M. Randi The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis Blood 119 2012 894 903
40. A. Chow, Y. Amemiya, L. Sugar, R. Nam, and A. Seth Whole-transcriptome analysis reveals established and novel associations with TMPRSS2:ERG fusion in prostate cancer Anticancer Res 32 2012 3629 3641
41. K. Grupp, S. Kohl, H. Sirma, R. Simon, S. Steurer, A. Becker, M. Adam, J. Izbicki, G. Sauter, S. Minner, T. Schlomm, and M.C. Tsourlakis Cysteine-rich secretory protein 3 overexpression is linked to a subset of PTEN-deleted ERG fusion-positive prostate cancers with early biochemical recurrence Mod Pathol 26 2013 733 742
42. M.I. Vitolo, A.E. Boggs, R.A. Whipple, J.R. Yoon, K. Thompson, M.A. Matrone, E.H. Cho, E.M. Balzer, and S.S. Martin Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin Oncogene 32 2013 2200 2210
43. J.L. Thielen, K.G. Volzing, L.S. Collier, L.E. Green, D.A. Largaespada, and P.C. Marker Markers of prostate region-specific epithelial identity define anatomical locations in the mouse prostate that are molecularly similar to human prostate cancers Differentiation 75 2007 49 61 (Pubitemid 46115413)